Company Description
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.
It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| Founded | 1987 |
| IPO Date | Dec 5, 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,543 |
| CEO | John Joseph Trizzino B.S., M.B.A. |
Contact Details
Address: 700 Quince Orchard Road Gaithersburg, Maryland 20878 United States | |
| Phone | 240-268-2000 |
| Website | novavax.com |
Stock Details
| Ticker Symbol | NVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001000694 |
| CUSIP Number | 670002401 |
| ISIN Number | US6700024010 |
| Employer ID | 22-2816046 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| John Joseph Trizzino B.S., M.B.A. | President and Chief Operating Officer |
| James Patrick Kelly C.F.A. | Executive Vice President, Chief Financial Officer and Treasurer |
| Stanley Charles Erck | Advisor |
| John Charles Jacobs M.B.A. | Chief Executive Officer and Director |
| Richard P. Crowley | Executive Vice President and Chief Operating Officer |
| Troy Morgan Esq., J.D. | Senior Vice President and Chief Compliance Officer |
| Mark Casey | Executive Vice President, Chief Legal Officer and Corporate Secretary |
| Erika S. Trahan | Associate Director of Investor and Public Relations |
| Ian J. Watkins | Executive Vice President and Chief Human Resources Officer |
| Silvia Taylor M.B.A. | Executive Vice President and Chief Corporate Affairs and Advocacy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 26, 2024 | 8-K | Current Report |
| Apr 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 15, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 28, 2024 | 10-K | Annual Report |